To characterize the disease course and visual outcome of uveitis in juvenile Behçet's disease (BD) compared with adults. The study population included 13 children (mean age 14±2.4 years; 22 eyes ...

Available treatments for Behcet's uveitis are limited to corticosteroids and off-label use of immunosuppressive drugs, which can have significant side effects especially when used on a chronic basis.

Servier has received authorization to initiate a phase 3 clinical trial in several European countries to analyze the efficacy and safety of gevokizumab compared with placebo in reducing the risk ...

Tacrolimus is not used commonly in the treatment of Behçet uveitis but has been reported to be effective in patients refractory to ciclosporin-A. [183] It is used at doses of 0.03–0.08 mg/kg daily.

August 29, 2012 — The US Food and Drug Administration (FDA) has granted orphan drug status to gevokizumab (Xoma 052, Xoma Corp), a monoclonal antibody that binds strongly to interleukin 1β (IL ...

The objective of the Phase 3 EYEGUARD-B study (A randomisEd, double-masked, placebo-controlled studY of the Efficacy of GevokizUmAb in the tReatment of patients with Behçet's Disease uveitis) was ...

XOMA retains development and commercialization rights for Behcet's uveitis and other inflammatory and oncology indications in U.S. and Japan. Servier receives similar rights in the rest of the world.

Self-reported general health was more impaired than visual function among patients with Behçet's uveitis, according to a study. "Several demographic and clinical variables had a significant ...

Posterior uveitis affects the choroid, retina, and optic nerve at the back of the eye, and it's often caused by infections or autoimmune diseases such as toxoplasmosis, herpes, or Behcet's disease.

XOMA 052, a potent anti-IL-1 beta antibody entering Phase 3 clinical development in Behcet's uveitis, for which it has been designated an orphan drug, and in Phase 2 clinical development for Type ...

Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295–296. Article CAS Google Scholar ...

Gevokizumab already has orphan drug designation in the U.S. for noninfectious and Behçet’s uveitis. “We launched our proof-of-concept program for gevokizumab just over two years ago.